This is an aggregated industry headline. Read the full story at FiercePharma →
FTC orders Aurobindo to divest 4 drugs to complete $250M Lannett acquisition
Before Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to divest four drugs from the proposed $250 million buyout to resolve anticompetitive concerns, the Federal Trade Commission said.
By FiercePharma
· Jun 19, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekFierceBiotech ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekBriefing
Three Asia-linked developments stood out: a CEO exit at Legend, a quickly deleted Merck trial posting, and an …